StockData

Liquidia vs Mirum Pharmaceuticals

LQDA and MIRM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LQDA and MIRM compare

Mirum Pharmaceuticals is the larger company, worth 1.2 times as much as Liquidia ($6.0B against $5.1B).

Liquidia grew revenue faster over the last twelve months (2234% versus 44.0% for Mirum Pharmaceuticals).

Liquidia keeps more of each dollar of sales as profit, with a net margin of 30.7% compared with −139% at Mirum Pharmaceuticals.

Liquidia scores higher on the StockData Score (8 against 5 for Mirum Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLQDAMIRM
Size and price
Market cap$5.1B$6.0B
Share price$56.73$91.95
Change, 1 year102%28.7%
Change, 5 years1280%586%
Beta (5Y)1.000.61
Employees216372
StockData Score
Total score8 (better)5
Valuation score00
Growth score23 (better)
Performance score3 (better)1
Health score3 (better)1
Dividend score00
Valuation
P/E40.8×–
P/S11.3×9.7× (better)
P/B26.0×–
EV/EBITDA28.2×–
P/FCF33.7×–
FCF yield3.0% (better)−3.8%
Fair value$32.46–
Margin of safety−74.8%–
Growth
Revenue growth (TTM)2234% (better)44.0%
Revenue growth, 5Y average192%–
Profitability
Operating margin37.4% (better)−135%
Net margin30.7% (better)−139%
FCF margin33.4% (better)−37.0%
Return on equity132% (better)−703%
Financial health
Interest coverage6.3× (better)−62.1×
Current ratio2.312.86 (better)
Altman Z-score10.49 (better)−0.22
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions81.1%110%
Held by insiders19.5%9.2%
Insider net buying, 12 months−$227M−$32.8M (better)
Short interest, % of float24.3%11.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.